Introduction
============

Endoscopic submucosal dissection (ESD) is recently developed technique that has made endoscopic resection of large gastric lesions possible.^([@B1])^ A recent study showed that proton pump inhibitors (PPIs) more effectively prevented bleeding due to ESD-induced gastric ulcers than histamine H~2~-receptor antagonists.^([@B2])^ Mucosal protective agents developed in Japan have been used for the treatment of upper gastrointestinal ulcers. The generally assumed mechanism underlying the action of these agents involves the up-regulation of gastric mucosal defenses during recovery of mucosal tissue. Mucosal protective agents include drugs such as rebamipide, ecabet sodium, polaprezinc, sucralfate, sodium alginate, plaunotol, sofalcone, teprenone, irsogladine maleate, misoprostol, and aluminum-magnesium hydroxide, which are widely prescribed, in East Asia.^([@B3],[@B4])^

A meta-analysis study recently demonstrated that treatment of ESD-induced ulcers with PPIs plus rebamipide results in superior outcomes to PPI monotherapy.^([@B5])^ The healing rates of ESD-induced ulcers might be improved by not only rebamipide but also other mucosal protective agents. Several studies have also examined the efficacy of other mucosal protective agents with PPI for the treatment of ESD-induced ulcers. Our objective was to perform a systematic review and meta-analysis of published randomized controlled trials (RCTs) in order to evaluate the efficacy of treatment with PPI plus mucosal protective agents.

Methods
=======

Before performing the meta-analysis, we developed a protocol that included search strategies, criteria for study selection, the method of extraction of related data, methods for assessing study quality, and statistical methodology.

Search strategy
---------------

The electronic databases PubMed, the Cochrane Library, and the Igaku-Chuo-Zasshi in Japan (from 1950 to June 2014) were used to systematically search the literature for a combination of the following words: (endoscopic submucosal dissection OR ESD) AND (mucosal protective agents, mucosal defensive agents, rebamipide, ecabet sodium, polaprezinc, sucralfate, alginate, plaunotol, sofalcone, teprenone, irsogladine, misoprostol, OR aluminum-magnesium). Articles published in any language were included. Although abstracts occasionally include less information and may possess less accuracy, we retrieved them to reduce publication bias; in essence, studies with negative results are less likely to reach full publication.

Inclusion and exclusion criteria
--------------------------------

Articles were considered eligible if the studies met the following inclusion criteria: (1) study type: RCTs; (2) population: patients who had undergone ESD; (3) intervention: an active treatment with PPI plus mucosal protective agents; (4) comparison group: treatment with PPI monotherapy; (5) outcome: reported healing rates of ESD-induced ulcers. The major exclusion criteria were: (1) a non-RCT; (2) administration of rebamipide in the control group; (3) no ulcer healing rates reported; or (4) duplicate publications, case reports and reviews.

Data extraction
---------------

Standardized data abstraction sheets were prepared. Data were extracted for study quality, endoscopic therapy use, medication duration, patient follow-up time, and sex and age of enrolled subjects. Key outcome data were abstracted from all included studies. All articles were examined independently for eligibility by two reviewers (T.N. and H.S.). Disagreements were resolved by consulting a third reviewer (N.Y.).

Outcome measures
----------------

The primary outcome measured was healing rates of ESD-induced ulcers. The ulcer stage was classified using the classification of Sakita and Miwa: active (A1 and A2), healing (H1 and H2), and scaring (S1 and S2).^([@B6])^ S-stage was defined as the healing of an artificial ulcer. The secondary outcome measured was safety, which was analyzed by evaluating complication rates.

Assessment of methodological quality
------------------------------------

The methodological quality of each study was assessed using the risk-of-bias tool outlined in the Cochrane Handbook for Systematic Reviews of Interventions (ver. 5.1.0). Two reviewers (T.N. and H.S.) reviewed all studies and assessed 6 key aspects influencing quality of an RCT, including sequence generation, allocation concealment, blinding of both participants and outcome assessors, management of eventual incomplete outcome data, completeness of outcome reporting, and other potential threats to validity.

Statistical analysis
--------------------

Data were entered into StatsDirect statistical software. The odds ratios (ORs) were calculated for ulcer healing rates with PPI plus mucosal protective agents were compared to that with PPI monotherapy. We used a random-effect model to calculate summary ORs and 95% confidence intervals (CIs). Heterogeneity between the studies was assessed using Cochrane's Q and I-Squared test. Because of the low power of the Q test, a cut-off value \<0.10 was used to reject homogeneity, indicating heterogeneity. An I-squared score ⩾50% indicated more than moderate heterogeneity.^([@B7])^ The subgroup analyses were performed for each individual mucosal protective agent that allowed the groups to be classified into patients who had received four- and eight-week treatments. To evaluate the statistical stability of this meta-analysis, we performed a sensitivity analysis to evaluate the effect of low-quality studies (conference abstracts). Finally, we used funnel plot asymmetry to detect any publication bias in the meta-analysis, and Egger's regression test to measure funnel plot asymmetry.

Results
=======

Literature search
-----------------

Our database search yielded 109 citations (Fig. [1](#F1){ref-type="fig"}). After adjusting for duplicates, 63 studies remained. Of these, 37 studies were removed from consideration after reviewing the abstracts, based on exclusion criteria (20 unrelated topics, 5 reviews, 4 case reports, and 8 animal studies). The remaining 26 studies were examined in detail. Studies were then excluded due to lack of randomization (*n* = 6), control groups (*n* = 7), or reported ulcer healing rates (*n* = 2 conference abstracts).^([@B8],[@B9])^ Finally, 11 studies (8 full papers and 3 conference abstracts) were included in the systematic review and meta-analysis.^([@B10]--[@B20])^

Characteristics and quality of eligible studies
-----------------------------------------------

The characteristics of the 11 studies are summarized in Table [1](#T1){ref-type="table"}. The risk of bias in the RCTs is shown in Table [2](#T2){ref-type="table"}. In general, the 8 full paper studies in the analysis had low risk of bias. The 3 conference abstracts had an unclear risk of bias. Six RCTs (3 full papers and 3 abstracts) did not describe the specific methods of random sequence generation and allocation concealment. Methods of blindness assessment were not described for 7 studies (4 full papers and 3 abstracts). The 3 abstracts did not adequately assess incomplete outcomes or how selective outcome reporting was avoided. All 8 full paper studies were free of other biases.

Efficacy analysis
-----------------

Pooled healing rates were achieved for 266 of 581 patients (45.8%) treated with mucosal protective agents and for 199 of 579 patients (34.4%) who had not received mucosal protective agents (OR 2.28, 95% CI 1.57--3.31, *p*\<0.0001, Fig. [2](#F2){ref-type="fig"}). There was no significant heterogeneity among the trial results (χ^2^ = 13.0, *p* = 0.225, I^2^ = 23%). In the subgroup analysis based on duration of treatment, we found that treatment with PPIs plus mucosal protective agents was more effective in healing ESD-induced ulcers than PPI monotherapy over both four-(OR 2.19, 95% CI 1.43--3.34, *p* = 0.0003, Fig. [3](#F3){ref-type="fig"}) and eight-week treatments (OR 3.03, 95% CI 1.42--6.48, *p* = 0.0043, Fig. [4](#F4){ref-type="fig"}).

Additive effects of individual mucosal protective agents were also analyzed (Table [3](#T3){ref-type="table"}). Rebamipide and irsogladine were significantly effective, but the study on irsogladine was one of the conference abstracts. Ecabet sodium and polaprezinc were not significantly effective.

Adverse events
--------------

Three trials reported adverse events. The study by Fujiwara *et al.*^([@B11])^ reported that one patient in the PPI group experienced bleeding due to a post-ESD artificial ulcer. There were no other serious adverse events.

Sensitivity analysis and publication bias
-----------------------------------------

To analyze statistical sensitivity of our meta-analysis, we excluded three low-quality studies (conference abstracts). Exclusion of these studies did not significantly alter the outcome of the meta-analysis. (OR 2.40, 95% CI 1.58--3.65, *p*\<0.0001, Fig. [5](#F5){ref-type="fig"}). The funnel plot had almost symmetrical distribution (Fig. [6](#F6){ref-type="fig"}), and Egger's regression test suggested no significant asymmetry of the funnel plot (*p* = 0.15), indicating no evidence of substantial publication bias.

Discussion
==========

This systematic review and meta-analysis indicated that therapeutic use of PPIs plus mucosal protective agents is superior to PPI monotherapy for ESD-induced ulcers. We therefore expect that mucosal protective agents will become more widely utilized for treatment of ESD-induced ulcers.

Mucosal protective agents are safe and widely used as anti-ulcer drugs in East Asia. Rebamipide {2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinon-4-yl\] propionic acid; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan} exerts a preventive effect on gastric ulcer formation by inhibiting neutrophil activation.^([@B21],[@B22])^ Rebamipide is an oxygen-radical scavenger, stimulates the generation of cytoprotective prostaglandins, and increases blood flow in the gastric mucosa.^([@B23]--[@B25])^ Ecabet sodium (12-sulfodehydroabietic acid monosodium salt; Mitsubishi Tanabe Pharma Corporation, Osaka, Japan) has protective effects such as endogenous prostaglandins and nitric oxide synthesis and increases blood flow in the gastric mucosa.^([@B26])^ Ecabet sodium also exhibits a bactericidal effect against *Helicobacter pylori* by inhibiting bacterial urease activity.^([@B27])^ Polaprezinc \[*N*-(3-amino propionyl)-[l]{.smallcaps}-histidine zinc; Zeria Pharmaceutical Co., Ltd., Tokyo, Japan\] promotes ulcer healing with actions such as prostaglandin-independent cytoprotection, antioxidant activity, leukocyte inactivation, and membrane stabilization.^([@B28])^ Moreover, polaprezinc stimulates the production of insulin-like growth factor 1, thus promoting mucosal wound healing.^([@B29])^ Irsogladine \[2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine; Nippon Shinyaku Co., Ltd., Kyoto, Japan\] suppresses free radical production, facilitates intercellular communication via gap junctions, and enhances gastric mucosal blood flow.^([@B30])^ These actions accelerate mucosal or submucosal reconstruction and enhance the quality of ulcer healing.

In clinical practice, it is important to understand which mucosal protective agents are most effective for improving healing of gastric ulcers. Among the drugs analyzed in our study, rebamipide and irsogladine were significantly effective. However, the study on irsogladine was of low quality. Further, it was difficult to evaluate whether Ecabet sodium and polaprezinc were effective because the sample sizes in these studies were not large enough to uncover significant differences. Although rebamipide seems most effective, well-designed trials are needed to confirm these findings.

The costs of rebamipide, ecabet sodium, polaprezinc, and irsogladine for 28 days are ¥1,462, ¥1,271, ¥2,106, and ¥1,840, respectively. The costs of rabeprazole (20 mg/day) and lansoplazole (30 mg/day) for 28 days are ¥7,448 and ¥4,648, respectively. The costs of mucosal protective agents are relatively low. Takayama *et al.*^([@B15])^ reported that rebamipide monotherapy was equivalent to treatment with a PPI in the healing of ESD-induced ulcers and treatment with rebamipide was more cost-effective than treatment with the PPI. Mucosal protective agents might be able to reduce the costs by reducing the dose of PPI.

The present systematic review and meta-analysis has several limitations that need to be taken into account when interpreting the results. None of the included RCT trials met all quality criteria, which may have influenced the results. In addition, most participants in the studies were Japanese and Korean; therefore, these results may not be generalizable to other races.

In conclusion, our analysis demonstrates that supplementing PPI therapy with mucosal protective agents could improve healing of ESD-induced ulcers.
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###### 

Characteristics of studies included in the meta-analysis

  Author Year      Country                                             Mucosal protective agents   Patients number   Intervention                                    Duration (days)
  ---------------- --------------------------------------------------- --------------------------- ----------------- ----------------------------------------------- -----------------
  Kato 2010        Japan                                               Rebamipide                  31                RPZ 10 mg/day                                   28
  31               RPZ + rebamipide 300 mg/day                                                                                                                       
                                                                                                                                                                     
  Fujiwara 2011    Japan                                               Rebamipide                  31                OPZ 20 mg/day                                   56
  30               OPZ + rebamipide 300 mg/day                                                                                                                       
                                                                                                                                                                     
  Araki 2012       Japan                                               Rebamipide                  42                OPZ 20 mg/day, LPZ 30 mg/day or RPZ 10 mg/day   28
  45               PPI + rebamipide 300 mg/day                                                                                                                       
                                                                                                                                                                     
  Kobayashi 2012   Japan                                               Rebamipide                  85                OPZ 20 mg/day or LPZ 30 mg/day                  28--42
  85               PPI + rebamipide 300 mg/day                                                                                                                       
                                                                                                                                                                     
  Shin 2012        Korea                                               Rebamipide                  129               Pantprazole 40 mg/day                           28
  126              Pantprazole + rebamipide 300 mg/day                                                                                                               
                                                                                                                                                                     
  Takayama 2013    Japan                                               Rebamipide                  44                LPZ 30 mg/day                                   28/56
  45               LPZ 30 mg/day, 5 days; then rebamipide 300 mg/day                                                                                                 
                                                                                                                                                                     
  Asakuma 2009     Japan                                               Ecabet                      27                RPZ 20 mg/day                                   28/56
  28               RPZ + ecabet 3 g/day                                                                                                                              
                                                                                                                                                                     
  Hyun 2010        Korea                                               Ecabet                      38                LPZ 30 mg/day                                   28
  38               LPZ 30 mg/day, 7 days; then ecabet 3 g/day                                                                                                        
                                                                                                                                                                     
  Inaba 2010       Japan                                               Polaprezinc                 80                LPZ 30 mg/day                                   56
  79               LPZ + polaprezinc 150 mg/day                                                                                                                      
                                                                                                                                                                     
  Yoshida 2013     Japan                                               Polaprezinc                 27                OPZ 20 mg/day                                   56
  23               OPZ + polaprezinc 150 mg/day                                                                                                                      
                                                                                                                                                                     
  Miyahara 2013    Japan                                               Irsogladine                 45                PPI                                             28
  51               PPI + irsogladine                                                                                                                                 

RPZ: rabeprazole, OPZ: omeprazole, LPZ: lansoprazole.

###### 

Evaluation of bias of RCTs included in the meta-analysis

  First author   Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Adequate assessment of incomplete outcome   Selective reporting avoided   No other bias
  -------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------------------------- ----------------------------- ---------------
  Kato           Yes                          Yes                      No                                       Unclear                          Yes                                         Yes                           Yes
  Fujiwara       Yes                          Yes                      No                                       Unclear                          Yes                                         Yes                           Yes
  Araki          Unclear                      Unclear                  No                                       Yes                              Yes                                         Yes                           Yes
  Kobayashi      Yes                          Yes                      No                                       Yes                              Yes                                         Yes                           Yes
  Shin           Yes                          Yes                      No                                       Yes                              Yes                                         Yes                           Yes
  Takayama       Unclear                      Unclear                  No                                       Unclear                          Yes                                         Yes                           Yes
  Asakuma        Unclear                      Unclear                  No                                       Unclear                          Yes                                         Yes                           Yes
  Hyun           Unclear                      Unclear                  No                                       Unclear                          Unclear                                     Unclear                       Unclear
  Inaba          Yes                          Yes                      No                                       Yes                              Yes                                         Yes                           Yes
  Yoshida        Unclear                      Unclear                  No                                       Unclear                          Unclear                                     Unclear                       Unclear
  Miyahara       Unclear                      Unclear                  No                                       Unclear                          Unclear                                     Unclear                       Unclear

Yes: low risk of bias, No: high risk of bias, Unclear: unclear risk of bias.

###### 

Pooled Odds ratio and its 95% CI in the studies of each mucosal protective agent

  Mucosal protective agent   Odds ratio   95% CI       Number of studies
  -------------------------- ------------ ------------ -------------------
  Rebamipide                 2.4          1.68--3.44   6
  Ecabet                     2.18         0.49--9.70   2
  Polaprezinc                1.89         0.44--7.91   2
  Irsogladine                5.24         1.08--25.4   1
